BMRN — BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue Growth: Year-to-date total revenue increased by 11% compared to the same period in 2024, driven by strong performance in enzyme therapies and skeletal conditions.
• VOXZOGO Revenue: Expected to generate between $900 million and $935 million for the full year 2025, representing a 25% growth at the midpoint of guidance.
• Operating Cash Flow: Reached $369 million in Q3 and $728 million year-to-date, contributing to a total cash and investments balance of approximately $2 billion.
• Non-GAAP Earnings Guidance: Updated non-GAAP diluted earnings per share guidance to between $3.50 and $3.60, with operating margin guidance adjusted to 26%-27%.
• IPR&D Charges: A $221 million charge related to the Inozyme Pharma acquisition impacted Q3 results, affecting both GAAP and non-GAAP earnings.

2. Strategic Updates and Business Highlights

• Business Units Performance: Enzyme Therapies unit saw 8% year-to-date growth, with PALYNZIQ and VOXZOGO each increasing over 20% year-to-date.
• Product Pipeline: VOXZOGO's second indication for hypochondroplasia is anticipated for a pivotal data readout in H1 2026, with a potential launch in 2027.
• Divestiture of ROCTAVIAN: BioMarin plans to divest its gene therapy ROCTAVIAN to focus on core business units aligned with strategic priorities.
• Global Expansion: VOXZOGO is now available in 55 countries, with strong uptake and adherence rates noted, particularly among children under 2 years old.

3. Forward Guidance and Outlook

• Revenue Guidance: Full-year total revenue guidance raised to a range of $3.15 billion, reflecting strong performance and expectations for Q4.
• Long-term Revenue Outlook: For 2027, the lower end of the revenue estimate aligns with current consensus ($3.65 billion excluding ROCTAVIAN), while the upper end could reach $4 billion, contingent on various competitive scenarios.
• Operating Margin and Cash Flow: Continued expectation for a 40% non-GAAP operating margin starting in 2026, with over $1.25 billion in cash flow anticipated starting in 2027, though these are dependent on top-line performance.

4. Bad News, Challenges, or Points of Concern

• Quarterly VOXZOGO Sales Decline: Noted a slight decline in VOXZOGO sales quarter-over-quarter due to timing of orders, although year-over-year growth remains strong.
• Competitive Pressures: Increased concern regarding potential competition for VOXZOGO, particularly from Ascendis and BridgeBio, leading to a reassessment of 2027 revenue guidance.
• Market Dynamics: Slower growth in older patient populations for VOXZOGO in the U.S. due to geographical dispersion and management by various specialties.
• IPR&D Impact: The significant charge from the Inozyme acquisition has raised R&D expenses and affected operating margins.

5. Notable Q&A Insights

• 2027 Guidance Clarification: Management emphasized that the 2027 revenue guidance is not a forecast but a range of scenarios reflecting competitive dynamics and potential outcomes.
• Business Development Strategy: BioMarin is actively pursuing business development opportunities, focusing on both early-stage collaborations and later-stage assets, given their strong cash position.
• DMD Program Ambitions: The company set a high bar of 10% dystrophin increase for their DMD program, emphasizing the importance of delivering meaningful results for patients.
• Orphan Drug Exclusivity: BioMarin is pursuing orphan drug exclusivity for VOXZOGO, with expectations tied to the upcoming PDUFA date.

Overall, BioMarin reported strong financial results and strategic growth initiatives while navigating competitive pressures and operational challenges.